Aberdeen Group plc Buys 13,173 Shares of DexCom, Inc. $DXCM

Key Points

• Aberdeen Group plc increased its stake in DexCom, Inc. by 3.8%, owning 360,724 shares valued at approximately $24.3 million, while institutional investors collectively hold 97.75% of the company's stock.
• DexCom's stock is currently trading at $81.67, reflecting a 1.0% increase, with a market capitalization of $32.03 billion and earnings per share (EPS) guidance for FY 2025.
• Analysts have a favorable outlook on DexCom, with three rating the stock as a Strong Buy and a target price averaging around $99.89.

Aberdeen Group plc boosted its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 3.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 360,724 shares of the medical device company's stock after buying an additional 13,173 shares during the quarter. Aberdeen Group plc owned approximately 0.09% of DexCom worth $24,311,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Horizon Investments LLC lifted its position in shares of DexCom by 2.2% during the first quarter. Horizon Investments LLC now owns 5,608 shares of the medical device company's stock worth $383,000 after purchasing an additional 123 shares in the last quarter. Nia Impact Advisors LLC raised its position in DexCom by 1.4% in the 4th quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock worth $766,000 after purchasing an additional 140 shares during the last quarter. Wedbush Securities Inc. lifted its holdings in DexCom by 1.2% during the 1st quarter. Wedbush Securities Inc. now owns 13,168 shares of the medical device company's stock worth $899,000 after buying an additional 157 shares in the last quarter. Argonautica Private Wealth Management Inc. boosted its position in DexCom by 3.2% in the 1st quarter. Argonautica Private Wealth Management Inc. now owns 5,958 shares of the medical device company's stock valued at $407,000 after buying an additional 182 shares during the last quarter. Finally, Trivium Point Advisory LLC increased its position in DexCom by 6.1% in the first quarter. Trivium Point Advisory LLC now owns 3,455 shares of the medical device company's stock worth $236,000 after purchasing an additional 200 shares during the period. Institutional investors and hedge funds own 97.75% of the company's stock.

DexCom Stock Performance

Shares of DXCM traded up $1.5890 during mid-day trading on Friday, reaching $82.2090. The company's stock had a trading volume of 1,358,604 shares, compared to its average volume of 3,862,880. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $93.25. The business has a 50-day simple moving average of $82.81 and a two-hundred day simple moving average of $79.93. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The stock has a market cap of $32.24 billion, a P/E ratio of 57.12, a PEG ratio of 1.71 and a beta of 1.43.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the previous year, the company earned $0.43 earnings per share. The company's quarterly revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 500 shares of the firm's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the completion of the sale, the executive vice president owned 94,102 shares of the company's stock, valued at $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the completion of the transaction, the director owned 51,121 shares in the company, valued at approximately $4,143,868.26. This represents a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 21,906 shares of company stock worth $1,832,451. Corporate insiders own 0.32% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on DXCM shares. Truist Financial assumed coverage on shares of DexCom in a report on Monday, June 16th. They set a "buy" rating and a $102.00 target price for the company. Wall Street Zen lowered shares of DexCom from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 10th. Raymond James Financial lifted their price target on shares of DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 31st. UBS Group boosted their price objective on shares of DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a research report on Thursday, July 31st. Finally, Robert W. Baird lowered their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $99.90.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.